Skip to main content
Premium Trial:

Request an Annual Quote

BioFire Files 510(k) Submission to FDA for Blood Culture Panel

NEW YORK (GenomeWeb News) – BioFire Diagnostics today announced the 510(k) submission of its FilmArray Blood Culture Identification, or BCID, Panel to the US Food and Drug Administration.

The submission follows the successful completion of clinical trials for the panel, which provides automatic results for the most common infectious causes of sepsis. BioFire said that pending clearance from FDA, it anticipates launching the panel in the summer.

The panel simultaneously tests positive blood cultures for about 90 percent of the gram-positive bacteria, gram-negative bacteria, and yeast microbes that cause bloodstream infections. Additionally, it tests for common antimicrobial resistance genes associated with methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, and carbapenem-resistant Enterobacteriaceae.

BioFire noted that a timely diagnosis and administration of treatments can reduce mortality rates, hospital stays, and healthcare costs resulting from sepsis.

"We believe the availability of the BCID Panel, the FDA-cleared Respiratory Panel and our gastrointestinal and meningitis panels will continue to increase the utility of the FilmArray in the hospital clinical laboratory," BioFire CEO Kirk Ririe said in a statement.

Formerly called Idaho Technology, BioFire received FDA clearance of its FilmArray Respiratory Panel in May 2011. FDA cleared five additional pathogens for the panel last year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.